Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris
Provided By Globe Newswire
Last update: Apr 26, 2023
Multiple Myeloma
AL Amyloidosis
Nexcella Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in light chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris
Read more at globenewswire.comNASDAQ:IMMX (5/9/2025, 8:00:55 PM)
2.09
-0.06 (-2.56%)
Find more stocks in the Stock Screener
